[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"chain-detail":3,"chain-related-fa3b59f4-0fc7-4f9d-bff0-94d4498b3e7c":1030,"chain-scenarios-fa3b59f4-0fc7-4f9d-bff0-94d4498b3e7c":1038,"chain-expert-resolve-fa3b59f4-0fc7-4f9d-bff0-94d4498b3e7c":1040,"chain-related":1059},{"id":4,"name":5,"category":6,"groupCategory":7,"intro":8,"scale":9,"maturity":10,"meta":11,"checkState":626,"version":490,"createdBy":197,"createdAt":627,"updatedAt":628,"nodes":629},"fa3b59f4-0fc7-4f9d-bff0-94d4498b3e7c","医药制造产业链（传统）","传统产业","TRADITIONAL","化学药、中药、生物药传统制造","2025年规模以上医药工业企业营业收入约2.96万亿元(国家统计局);中国生物医药市场规模约2.24万亿元(行业研究机构口径,2025)","转型期",{"ipc":12,"trl":22,"tier":25,"codes":26,"trade":29,"counts":39,"market":43,"source":84,"experts":85,"shaanxi":134,"sources":135,"clusters":141,"maturity":10,"policies":239,"source60":244,"chainCode":28,"matched60":245,"bottlenecks":246,"competition":478,"subCategory":522,"lifecycleStage":523,"strategic_note":75,"strategic_path":524,"key_technologies":528,"national_policies":538,"value_chain_profile":580,"regional_distribution":605},[13,16,19],{"code":14,"meaning":15},"A61K 31\u002F00","含机活性成份的医药配制品(小分子药)",{"code":17,"meaning":18},"A61K 39\u002F00","含抗原\u002F抗体的医药配制品(疫苗\u002F生物药)",{"code":20,"meaning":21},"C07K 16\u002F00","免疫球蛋白\u002F单克隆抗体",{"basis":23,"range":24},"创新药\u002F疫苗\u002F高端器械已规模上市(TRL8-9)，前沿管线(ADC\u002FCGT)在临床(TRL5-7)","TRL7–9","新兴支柱",[27,28],"E20","T12",{"exports":30,"sources":31,"dependence":34,"export_yoy":35,"export_label":36,"export_value":37,"imports_note":38},"2025年创新药对外授权交易总额1356.55亿美元（首付款70亿美元、157笔），创历史新高",[32,33],"https:\u002F\u002Fwww.gov.cn\u002Flianbo\u002F202601\u002Fcontent_7053894.htm","http:\u002F\u002Fwww.ce.cn\u002Fxwzx\u002Fgnsz\u002Fgdxw\u002F202601\u002Ft20260105_2681821.shtml","高端医疗器械核心部件、原研创新药对外依存；原料药为净出口大国","+约161%（约2.5倍）","创新药对外授权(License-out)总额","1356.55亿美元","高端原研药、大型影像设备(高端MRI\u002FCT)、部分重组蛋白试剂\u002F培养基仍依赖进口",{"clusters":40,"segments":41,"companies":42,"bottlenecks":41},6,9,16,{"china":44,"global":71,"output":76,"sources":77,"output_yoy":80,"extra_market":81,"output_label":82,"output_value":83},{"yoy":45,"note":46,"breakdown":47,"donut_sub":66,"size_2025":67,"donut_title":68,"donut_center":69,"with_equipment_materials":70},"-1.2%（医药制造业营收）","份额按规上医药工业营收29562.5亿元测算，部分为估算；医疗器械市场(约1.22万亿)单列见with_equipment_materials",[48,53,57,62],{"yoy":49,"size":50,"share":51,"segment":52},"—","约13300亿元","45%","化学药（制剂+原料药）",{"yoy":49,"size":54,"share":55,"segment":56},"约8000亿元","27%","中药（饮片+中成药）",{"yoy":58,"size":59,"share":60,"segment":61},"+18.4%","约5900亿元","20%","生物药（单抗\u002F疫苗\u002F血制）",{"yoy":49,"size":63,"share":64,"segment":65},"约2400亿元","8%","其他（辅料\u002F包装\u002F制药设备等）","2025规上医药工业营收","规上医药工业营收29562.5亿元（MIIT）；规上医药制造业营收24870亿元(统计局，-1.2%)","中国医药工业结构 · 2025","2.96万亿元","含医疗器械市场约1.22万亿元（弗若斯特沙利文\u002F中物联医械）",{"yoy":72,"note":73,"size_2025":74,"yoy_2026e":75,"size_2026e":75},"规上医药工业增加值十四五年均+4.1%","全球药品市场约1.5万亿美元行业口径；中国是全球最主要原料药生产国和出口国，创新药管线全球第二","中国规上医药工业营收约2.96万亿元（MIIT 2025）；在研新药管线约占全球30%、居全球第二","","2025年国家药监局批准创新药76个，创历史新高（2024年为48个）",[32,78,79],"https:\u002F\u002Fwww.miit.gov.cn\u002Fjgsj\u002Fxfpgys\u002Fyy\u002Fart\u002F2026\u002Fart_f18b30d0f5fd4635b6544c6d13097b98.html","http:\u002F\u002Fwww.news.cn\u002F20251127\u002Ff0bafe03b5f448d39911beed092c5f83\u002Fc.html","+58%","2025年中国医疗器械市场约1.22万亿元，全球第二大单体市场、占全球约25%","年批准创新药数量","76个","全产业智慧图谱数据库（公开版）",[86,92,97,102,107,112,117,123,129],{"org":87,"raw":88,"name":89,"note":90,"title":91},"中国药科大学","王广基（中国药科大学），中国工程院院士，药物代谢动力学专家，江苏省药物代谢动力学重点实验室主任","王广基","药物代谢动力学专家，江苏省药物代谢动力学重点实验室主任","中国工程院院士",{"org":93,"raw":94,"name":95,"note":96,"title":91},"中国科学院上海药物研究所","丁健（中国科学院上海药物研究所），中国工程院院士，肿瘤药理学家，长期从事抗肿瘤新药研发","丁健","肿瘤药理学家，长期从事抗肿瘤新药研发",{"org":93,"raw":98,"name":99,"note":100,"title":101},"陈凯先（中国科学院上海药物研究所），中国科学院院士，药物设计专家，“重大新药创制”科技重大专项技术副总师","陈凯先","药物设计专家，“重大新药创制”科技重大专项技术副总师","中国科学院院士",{"org":103,"raw":104,"name":105,"note":106,"title":91},"中国医学科学院药物研究所\u002F兰州大学","王锐（中国医学科学院药物研究所\u002F兰州大学），中国工程院院士，多肽药物化学与多肽新药创制专家","王锐","多肽药物化学与多肽新药创制专家",{"org":108,"raw":109,"name":110,"note":111,"title":91},"温州医科大学","李校堃（温州医科大学），中国工程院院士，生长因子类生物药研究与产业化专家","李校堃","生长因子类生物药研究与产业化专家",{"org":113,"raw":114,"name":115,"note":116,"title":101},"中山大学肿瘤防治中心","马骏（中山大学肿瘤防治中心），中国科学院院士，鼻咽癌临床诊疗与创新药物临床研究专家","马骏","鼻咽癌临床诊疗与创新药物临床研究专家",{"org":118,"raw":119,"name":120,"note":121,"title":122},"华东理工大学","谭文松（华东理工大学），教授，动物细胞大规模培养与无血清培养基技术专家，倍谙基创始人","谭文松","动物细胞大规模培养与无血清培养基技术专家，倍谙基创始人","教授",{"org":124,"raw":125,"name":126,"note":127,"title":128},"西安交通大学","贺浪冲（西安交通大学），二级教授，细胞膜色谱与中药活性筛选，国家技术发明二等奖","贺浪冲","细胞膜色谱与中药活性筛选，国家技术发明二等奖","二级教授",{"org":130,"raw":131,"name":132,"note":133,"title":91},"空军军医大学","张生勇（空军军医大学），中国工程院院士，手性药物合成","张生勇","手性药物合成","医药和医疗装备",[136,137,138,139,140],"https:\u002F\u002Fwww.wuxiapptec.com.cn","https:\u002F\u002Fresources.asymchem.com.cn\u002FcasymchemMain\u002Fchannels\u002F236.html","https:\u002F\u002Fwww.hengrui.com\u002Fen\u002Fabout.html","https:\u002F\u002Fwww.stcn.com\u002Farticle\u002Fdetail\u002F3704297.html","http:\u002F\u002Fwww.sse.com.cn\u002Fassortment\u002Ffund\u002Flist\u002Fetfinfo\u002Fbasic\u002Findex.shtml?FUNDID=512010",[142,146,149,152,156,159,162,165,168,171,174,177,180,183,186,188,191,194,198,201,203,206,208,211,214,217,220,223,226,229,231,234,237],{"city":143,"name":144,"level":145},"泰州市","泰州市、连云港市、无锡市生物医药集群","国家级",{"city":147,"name":148,"level":145},"台州市","台州湾经济技术开发区",{"city":150,"name":151,"level":145},"沧州市","沧州临港经济技术开发区",{"city":153,"name":154,"level":155},"绍兴市","新昌高新技术产业园区","省级",{"city":157,"name":158,"level":145},"淄博市","淄博齐鲁化学工业区",{"city":160,"name":161,"level":145},"上海市","上海市张江生物医药集群",{"city":163,"name":164,"level":145},"苏州市","苏州市生物医药及高端医疗器械集群",{"city":166,"name":167,"level":145},"北京市","中关村科技园区大兴生物医药产业基地",{"city":169,"name":170,"level":145},"成都市","成渝地区生物医药集群",{"city":172,"name":173,"level":145},"汉中","汉中经济技术开发区生物医药产业园",{"city":175,"name":176,"level":145},"咸阳","咸阳高新技术产业开发区医药产业园",{"city":178,"name":179,"level":155},"亳州市","亳州现代中药产业集聚发展基地",{"city":181,"name":182,"level":145},"昆明市","昆明国家生物产业基地",{"city":184,"name":185,"level":145},"长春市","长春新区",{"city":143,"name":187,"level":145},"泰州医药高新技术产业开发区",{"city":160,"name":189,"level":190},"上海临港奉贤园区生命蓝湾","市级",{"city":192,"name":193,"level":145},"深圳市","深圳市、广州市高端医疗器械集群",{"city":195,"name":196,"level":197},"浦东—闵行—嘉定三区联动","上海高端医疗器械产业集聚区",null,{"city":199,"name":200,"level":190},"新乡市","新乡长垣医用卫材产业集群",{"city":166,"name":202,"level":145},"中关村昌平园",{"city":204,"name":205,"level":145},"武汉市","武汉临空港经济技术开发区",{"city":192,"name":207,"level":145},"深圳空港型国家物流枢纽",{"city":209,"name":210,"level":145},"郑州市","郑州空港型国家物流枢纽",{"city":212,"name":213,"level":197},"外高桥、洋山港物流集群","上海国际航运中心",{"city":215,"name":216,"level":145},"天津市","天津经济技术开发区",{"city":218,"name":219,"level":197},"马山","无锡",{"city":221,"name":222,"level":145},"无锡市","无锡高新技术产业开发区",{"city":224,"name":225,"level":197},"BioBAY","苏州生物医药产业园",{"city":227,"name":228,"level":145},"南京市","南京经济技术开发区",{"city":166,"name":230,"level":145},"中关村生命科学园",{"city":232,"name":233,"level":145},"东莞市","东莞松山湖高新技术产业开发区",{"city":235,"name":236,"level":197},"生工生物工程DNA合成基地","上海",{"city":163,"name":238,"level":145},"苏州工业园区",[240,241,242,243],"十四五医药工业发展规划","创新药\u002F医疗器械优先审评审批","医保谈判与商保目录支持创新","CXO应对美国《生物安全法案》等地缘政策","全产业60链图谱",true,[247,277,323,351,370,388,403,425,451],{"name":248,"risk":249,"type":250,"status":251,"experts":252,"policies":253,"progress":261,"companies":262,"policy_support":276},"高端医学影像(MRI\u002FCT)球管探测器","风险：高","设备","已突破",[],[254],{"raw":255,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":260},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：支持高端医学影像设备关键部件国产化与创新审批。","2025-01","国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见","国办发〔2024〕53号","国务院办公厅","支持高端医学影像设备关键部件国产化与创新审批。","联影3.0T MRI\u002F256排CT国产",[263,266,269,272,274],{"name":264,"note":265},"昆山医源","医用CT球管国产化主要厂商",{"name":267,"note":268},"麦默真空","CT球管",{"name":270,"note":271},"联影医疗","688271，自研球管与探测器",{"name":273,"note":197},"东软医疗",{"name":275,"note":268},"科罗诺司","医疗装备",{"name":278,"risk":279,"type":280,"status":281,"experts":282,"policies":289,"progress":302,"companies":303,"policy_support":322},"ADC\u002F双抗创新生物药","风险：中","工艺技术","国产替代",[283,286],{"org":93,"raw":284,"name":95,"note":285,"title":91},"丁健（中国科学院上海药物研究所），中国工程院院士，抗肿瘤新药研发","抗肿瘤新药研发",{"org":113,"raw":287,"name":115,"note":288,"title":101},"马骏（中山大学肿瘤防治中心），中国科学院院士，肿瘤临床研究与创新药临床试验","肿瘤临床研究与创新药临床试验",[290,296],{"raw":291,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":295},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：支持高临床价值创新药加快进入医保与商保目录。","2025-07","支持创新药高质量发展的若干措施","国家医保局、国家卫生健康委","支持高临床价值创新药加快进入医保与商保目录。",{"raw":297,"date":298,"name":299,"doc_no":197,"issuer":300,"summary":301},"《商业健康保险创新药品目录（2025年）》（国家医保局、人力资源社会保障部，2025-12）：纳入CAR-T等19种高值创新药，支持高值创新疗法支付。","2025-12","商业健康保险创新药品目录（2025年）","国家医保局、人力资源社会保障部","纳入CAR-T等19种高值创新药，支持高值创新疗法支付。","荣昌\u002F百济\u002F君实多款获批",[304,307,310,313,316,319],{"name":305,"note":306},"百利天恒","688506，伦康依隆妥单抗为全球首个双抗ADC",{"name":308,"note":309},"荣昌生物","688331，维迪西妥单抗、泰它西普",{"name":311,"note":312},"科伦博泰","06990.HK，芦康沙妥珠单抗",{"name":314,"note":315},"康方生物","09926.HK，依沃西单抗AK112",{"name":317,"note":318},"恒瑞医药","600276",{"name":320,"note":321},"三生国健","688336","创新药",{"name":324,"risk":249,"type":197,"status":281,"experts":325,"policies":326,"progress":330,"companies":331,"policy_support":350},"高端介入耗材(可降解支架\u002F瓣膜)",[],[327],{"raw":328,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":329},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：支持高端植入介入类医疗器械创新与加快上市。","支持高端植入介入类医疗器械创新与加快上市。","微创、乐普多款获批",[332,335,338,341,344,347],{"name":333,"note":334},"微创医疗","00853.HK，Firesorb火鹮生物可吸收支架",{"name":336,"note":337},"乐普医疗","300003，NeoVas可降解支架、ScienCrown经导管主动脉瓣",{"name":339,"note":340},"佰仁医疗","688198，人工生物瓣膜与瓣中瓣系统",{"name":342,"note":343},"启明医疗","02500.HK，TAVR",{"name":345,"note":346},"沛嘉医疗","09996.HK",{"name":348,"note":349},"心脉医疗","688016，主动脉及外周介入","高值耗材",{"name":352,"risk":249,"type":197,"status":353,"experts":354,"policies":358,"progress":359,"companies":360,"policy_support":197},"抗体药无血清细胞培养基","部分突破",[355],{"org":118,"raw":356,"name":120,"note":357,"title":122},"谭文松（华东理工大学），教授，无血清培养基技术专家，倍谙基创始人","无血清培养基技术专家，倍谙基创始人",[],"国产培养基企业已在部分生物药项目中实现替代供应，高端定制化培养基仍以进口为主",[361,364,367],{"name":362,"note":363},"奥浦迈","688293，无血清培养基与CDMO",{"name":365,"note":366},"澳斯康生物","健顺生物",{"name":368,"note":369},"倍谙基","华东理工大学谭文松教授创立",{"name":371,"risk":249,"type":197,"status":353,"experts":372,"policies":373,"progress":374,"companies":375,"policy_support":197},"生物药层析纯化介质",[],[],"国产层析介质已实现部分产品突破并进入生物药供应体系，高端产品仍以进口为主",[376,379,382,385],{"name":377,"note":378},"纳微科技","688690，2025年营收9.25亿元，色谱填料与层析介质",{"name":380,"note":381},"博格隆","Bestchrom，Protein A亲和填料",{"name":383,"note":384},"赛分科技","688758，工业纯化填料",{"name":386,"note":387},"蓝晓科技","300487，层析介质与mRNA纯化材料",{"name":389,"risk":249,"type":197,"status":390,"experts":391,"policies":392,"progress":396,"companies":397,"policy_support":197},"高端CT球管","依赖进口",[],[393],{"raw":394,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":395},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：支持高端医学影像设备及其关键部件创新，加快审评审批。","支持高端医学影像设备及其关键部件创新，加快审评审批。","高端CT球管长期由国际厂商主导，国产替代正在推进",[398,399,400,402],{"name":264,"note":197},{"name":267,"note":197},{"name":401,"note":268},"珠海瑞能",{"name":275,"note":197},{"name":404,"risk":249,"type":197,"status":353,"experts":405,"policies":406,"progress":410,"companies":411,"policy_support":197},"医学影像设备用超导磁体与谱仪",[],[407],{"raw":408,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":409},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：支持高端医学影像设备产业链自主可控。","支持高端医学影像设备产业链自主可控。","联影医疗等已实现超导磁体、谱仪等核心部件自研配套并批量装机",[412,415,418,420,423],{"name":413,"note":414},"宁波健信超导","688805，全球排名第一的超导磁体独立供应商，主攻无液氦超导磁体",{"name":416,"note":417},"西部超导","688122，超导线材",{"name":270,"note":419},"688271",{"name":421,"note":422},"万东医疗","600055",{"name":424,"note":197},"深圳安科",{"name":426,"risk":279,"type":197,"status":353,"experts":427,"policies":428,"progress":432,"companies":433,"policy_support":197},"药用中性硼硅玻璃管",[],[429],{"raw":430,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":431},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：强化药品包材等关联审评与质量监管，支持关键药用包材国产化。","强化药品包材等关联审评与质量监管，支持关键药用包材国产化。","国内企业已实现中性硼硅玻璃管规模化生产，疫苗瓶等高端应用国产化率持续提升",[434,437,440,442,445,448],{"name":435,"note":436},"沧州四星玻璃","药用中性硼硅玻璃管主要厂商",{"name":438,"note":439},"山东药玻","600529",{"name":441,"note":197},"凯盛君恒",{"name":443,"note":444},"力诺药包","301188",{"name":446,"note":447},"正川股份","603976",{"name":449,"note":450},"旗滨集团","601636，药用玻璃布局",{"name":452,"risk":249,"type":197,"status":353,"experts":453,"policies":454,"progress":458,"companies":459,"policy_support":197},"mRNA疫苗递送系统与关键原料",[],[455],{"raw":456,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":457},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：支持重大传染病等领域创新药研发，组织实施创新药物研发国家科技重大专项。","支持重大传染病等领域创新药研发，组织实施创新药物研发国家科技重大专项。","国内多条mRNA疫苗管线进入临床阶段，脂质纳米颗粒（LNP）等关键原料国产化仍在推进",[460,463,466,469,472,475],{"name":461,"note":462},"艾博生物","自主LNP递送技术、可电离阳离子脂质",{"name":464,"note":465},"石药集团","巨石生物，mRNA原液—LNP包封—制剂全链条平台",{"name":467,"note":468},"斯微生物","mRNA疫苗与LNP递送系统",{"name":470,"note":471},"近岸蛋白","688137，T7 RNA聚合酶、加帽酶等mRNA原料酶",{"name":473,"note":474},"键凯科技","688356，PEG化脂质",{"name":476,"note":477},"瑞吉生物","mRNA疫苗与递送技术",{"notes":479,"pattern":483,"sources":484,"bar_title":487,"global_top":488,"domestic_rate":504},[480,481,482],"2025年中国创新药License-out交易总额1356.55亿美元（首付款70亿美元\u002F157笔），为2024年(519亿\u002F94笔)约2.5倍，占全球医药交易约49–50%","CXO全球领先：药明康德\u002F康龙化成\u002F凯莱英\u002F药明生物承接全球产能；集采压仿制、鼓励创新","2025年批准创新药76个创纪录，在研管线约占全球30%、居全球第二","仿制受集采承压、创新药出海爆发；CXO全球龙头，高端器械与原研药仍追赶MNC",[32,485,486],"https:\u002F\u002Fpdf.dfcfw.com\u002Fpdf\u002FH3_AP202602111819874195_1.pdf","https:\u002F\u002Fstcn.com\u002Farticle\u002Fdetail\u002F3678594.html","中国创新药License-out交易 · 2025",[489,493,496,500],{"rank":490,"share":49,"company":491,"revenue":492},1,"跨国药企MNC（辉瑞\u002F诺华\u002F默沙东等）","全球药品市场前十",{"rank":494,"share":49,"company":317,"revenue":495},2,"国内创新药龙头",{"rank":497,"share":49,"company":498,"revenue":499},3,"百济神州","泽布替尼(BTK)全球商业化",{"rank":501,"share":49,"company":502,"revenue":503},4,"药明康德\u002F药明生物","全球CXO龙头",{"items":505,"headline":518},[506,509,512,515],{"label":507,"value":508},"创新药License-out全球占比","约49–50%",{"label":510,"value":511},"原料药全球供给地位","全球最主要出口国",{"label":513,"value":514},"高端医疗器械(CT\u002FMRI)国产化率","约30–50%（联影等突破）",{"label":516,"value":517},"重组蛋白\u002F培养基上游","加速国产替代",{"sub":519,"label":520,"value":521},"全球第二（2025）","在研新药管线全球占比","约30%","医药（传统制药）","TRANSFORMATION",[525,526,527],"5 生物产业 → 5.1 生物医药产业 → 化学药品制剂(2720)\u002F生物药品(2761)\u002F基因工程药物和疫苗(2762)","5 生物产业 → 5.5 生物医学工程产业 → 医疗诊断监护治疗设备(3581)\u002F医疗实验室设备(3583)","1 新一代信息技术\u002F5 生物产业 → 医学研究和试验发展(7340，CXO)",[529,530,531,532,533,534,535,536,537],{"risk":249,"tech":248,"type":250,"status":251,"bottleneck":245,"domestic_status":261},{"risk":279,"tech":278,"type":280,"status":281,"bottleneck":245,"domestic_status":302},{"risk":249,"tech":324,"type":197,"status":281,"bottleneck":245,"domestic_status":330},{"risk":249,"tech":352,"type":197,"status":353,"bottleneck":245,"domestic_status":359},{"risk":249,"tech":371,"type":197,"status":353,"bottleneck":245,"domestic_status":374},{"risk":249,"tech":389,"type":197,"status":390,"bottleneck":245,"domestic_status":396},{"risk":249,"tech":404,"type":197,"status":353,"bottleneck":245,"domestic_status":410},{"risk":279,"tech":426,"type":197,"status":353,"bottleneck":245,"domestic_status":432},{"risk":249,"tech":452,"type":197,"status":353,"bottleneck":245,"domestic_status":458},[539,542,548,551,554,560,567,573],{"raw":540,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":541},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：提出审评审批提速、全生命周期监管等改革举措，促进医药产业高质量发展。","提出审评审批提速、全生命周期监管等改革举措，促进医药产业高质量发展。",{"raw":543,"date":544,"name":545,"doc_no":197,"issuer":546,"summary":547},"《医药工业数智化转型实施方案（2025—2030年）》（工业和信息化部等七部门，2025-04）：工信部联消费〔2025〕79号，到2027年制修订30项以上数智技术标准、研发推广100款以上高性能产品、建成100个以上数智药械工厂，到2030年规上医药工业企业基本实现数智化转型全覆盖。","2025-04","医药工业数智化转型实施方案（2025—2030年）","工业和信息化部等七部门","工信部联消费〔2025〕79号，到2027年制修订30项以上数智技术标准、研发推广100款以上高性能产品、建成100个以上数智药械工厂，到2030年规上医药工业企业基本实现数智化转型全覆盖。",{"raw":549,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":550},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：医保发〔2025〕16号，5方面16条措施，全链条支持创新药研发、准入与多元支付。","医保发〔2025〕16号，5方面16条措施，全链条支持创新药研发、准入与多元支付。",{"raw":552,"date":298,"name":299,"doc_no":197,"issuer":300,"summary":553},"《商业健康保险创新药品目录（2025年）》（国家医保局、人力资源社会保障部，2025-12）：首版商保创新药目录纳入19种药品，与基本医保目录错位互补，自2026年1月1日起实施。","首版商保创新药目录纳入19种药品，与基本医保目录错位互补，自2026年1月1日起实施。",{"raw":555,"date":556,"name":557,"doc_no":197,"issuer":558,"summary":559},"《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》（中国共产党中央委员会，2025-10）：提出加快生物医药等战略性新兴产业发展，强化高水平科技自立自强。","2025-10","中共中央关于制定国民经济和社会发展第十五个五年规划的建议","中国共产党中央委员会","提出加快生物医药等战略性新兴产业发展，强化高水平科技自立自强。",{"raw":561,"date":562,"name":563,"doc_no":564,"issuer":565,"summary":566},"《陕西省中医药强省三年行动方案（2024—2026年）》（陕政办发〔2024〕1号）（陕西省人民政府办公厅，2024-01）：部署中医药服务体系与中药产业提升，推进中医药强省建设","2024-01","陕西省中医药强省三年行动方案（2024—2026年）","陕政办发〔2024〕1号","陕西省人民政府办公厅","部署中医药服务体系与中药产业提升，推进中医药强省建设",{"raw":568,"date":569,"name":570,"doc_no":197,"issuer":571,"summary":572},"《陕西省培育千亿级高端药品和医疗器械产业创新集群行动计划》（陕西省发展和改革委员会，2024-10）：推动高端药品产业创新集群建设，咸阳、汉中、安康等布局专业化医药园区","2024-10","陕西省培育千亿级高端药品和医疗器械产业创新集群行动计划","陕西省发展和改革委员会","推动高端药品产业创新集群建设，咸阳、汉中、安康等布局专业化医药园区",{"raw":574,"date":575,"name":576,"doc_no":577,"issuer":578,"summary":579},"《关于建立省重点产业链“链长制”工作机制的通知》（陕办字〔2024〕20号）（陕西省委办公厅、省政府办公厅，2024）：省级重点产业链优化拓展为34条并建立链长制","2024","关于建立省重点产业链“链长制”工作机制的通知","陕办字〔2024〕20号","陕西省委办公厅、省政府办公厅","省级重点产业链优化拓展为34条并建立链长制",{"note":581,"sources":582,"value_add":584},"专利创新药附加值最高，集采后仿制药利润承压；占比为券商测算，口径差异较大",[485,583],"https:\u002F\u002Fwww.miit.gov.cn\u002Fjgsj\u002Fxfpgys\u002Fyy\u002Fart\u002F2026\u002Fart_269b715252ad4b1ea0d64ab55b935c43.html",[585,589,593,597,601],{"share":586,"stage":587,"margin":588},"约40–50%","创新药\u002F专利药研发","高（专利期毛利70–90%）",{"share":590,"stage":591,"margin":592},"约10–15%","CXO（CRO\u002FCDMO）","中高（25–40%）",{"share":594,"stage":595,"margin":596},"约15%","医疗器械（高值耗材\u002F设备）","中高",{"share":598,"stage":599,"margin":600},"约15–20%","原料药\u002F仿制药","低（集采后10–20%）",{"share":602,"stage":603,"margin":604},"约10%","中药","中",[606,609,612,616,619,623],{"scale":49,"layout":607,"region":236,"feature":608},"上海张江","张江药谷：CXO+创新药+医学影像全链条",{"scale":49,"layout":238,"region":610,"feature":611},"江苏苏州","BioBay：信达\u002F基石等创新药",{"scale":49,"layout":613,"region":614,"feature":615},"连云港","江苏连云港","恒瑞医药总部",{"scale":49,"layout":617,"region":617,"feature":618},"北京","百济\u002F科伦等创新药",{"scale":49,"layout":620,"region":621,"feature":622},"深圳","广东深圳","迈瑞\u002F创新药",{"scale":49,"layout":624,"region":624,"feature":625},"天津","凯莱英CDMO","VERIFIED","2026-10-09T13:20:56.387Z","2026-10-12T14:28:54.468Z",[630,672,720,776,818,857,911,953,989],{"id":631,"chainId":4,"layer":632,"segment":633,"name":633,"keyPoints":634,"companies":635,"sortOrder":651,"isKey":652,"checkState":626,"meta":653,"createdAt":670,"links":671},"cnH_T12_01","上游","原料药","化学原料药 中间体 中药材",[636,639,642,645,648],{"name":637,"note":638},"华海药业","600521，沙坦类等特色原料药与制剂一体化",{"name":640,"note":641},"普洛药业","000739，原料药+CDMO",{"name":643,"note":644},"九洲药业","603456，特色原料药与CDMO",{"name":646,"note":647},"天宇股份","300702，沙坦类原料药",{"name":649,"note":650},"陕西汉江药业集团股份有限公司","汉中，原料药与医药中间体",0,false,{"source":84,"experts":654,"policies":655,"chainCode":28,"aggregationZones":659},[],[656],{"raw":657,"date":544,"name":545,"doc_no":197,"issuer":546,"summary":658},"《医药工业数智化转型实施方案（2025—2030年）》（工业和信息化部等七部门，2025-04）：推动原料药等医药工业环节绿色化、数智化改造升级。","推动原料药等医药工业环节绿色化、数智化改造升级。",[660,662,664,666,668],{"city":143,"name":144,"note":661,"level":145},"化学原料药与制剂一体化（恒瑞医药等）",{"city":147,"name":148,"note":663,"level":145},"特色原料药与医药中间体制造配套",{"city":150,"name":151,"note":665,"level":145},"精细化工与医药中间体制造配套",{"city":153,"name":154,"note":667,"level":155},"维生素等特色原料药与精细化学品",{"city":157,"name":158,"note":669,"level":145},"基础化工原料与医药中间体配套","2026-10-12T14:28:54.479Z",[],{"id":673,"chainId":4,"layer":674,"segment":675,"name":675,"keyPoints":676,"companies":677,"sortOrder":490,"isKey":652,"checkState":626,"meta":694,"createdAt":718,"links":719},"cnH_T12_02","中游","化学制剂","仿制药 创新药 注射剂 口服制剂",[678,680,683,685,688,691],{"name":317,"note":679},"600276，创新药与仿制药龙头",{"name":681,"note":682},"中国生物制药","01177.HK",{"name":464,"note":684},"01093.HK",{"name":686,"note":687},"翰森制药","03692.HK",{"name":689,"note":690},"科伦药业","002422",{"name":692,"note":693},"西安杨森制药有限公司","西安，化学制剂生产，1985年成立",{"source":84,"experts":695,"policies":700,"chainCode":28,"aggregationZones":707},[696,697],{"org":93,"raw":284,"name":95,"note":285,"title":91},{"org":93,"raw":698,"name":99,"note":699,"title":101},"陈凯先（中国科学院上海药物研究所），中国科学院院士，药物设计与新药创制","药物设计与新药创制",[701,704],{"raw":702,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":703},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：支持创新药进入医保目录和商保创新药目录，提高多元支付能力。","支持创新药进入医保目录和商保创新药目录，提高多元支付能力。",{"raw":705,"date":298,"name":299,"doc_no":197,"issuer":300,"summary":706},"《商业健康保险创新药品目录（2025年）》（国家医保局、人力资源社会保障部，2025-12）：首版目录纳入19种高值创新药，拓展创新药支付渠道。","首版目录纳入19种高值创新药，拓展创新药支付渠道。",[708,710,712,714,716],{"city":160,"name":161,"note":709,"level":145},"创新药研发与化学制剂产业化集聚",{"city":143,"name":144,"note":711,"level":145},"化学药与创新药制剂制造集聚",{"city":163,"name":164,"note":713,"level":145},"创新药与制剂研发生产集聚",{"city":166,"name":167,"note":715,"level":145},"化学制剂与生物药研发生产集聚",{"city":169,"name":170,"note":717,"level":145},"创新药与制剂产业化配套","2026-10-12T14:28:54.483Z",[],{"id":721,"chainId":4,"layer":674,"segment":603,"name":603,"keyPoints":722,"companies":723,"sortOrder":494,"isKey":652,"checkState":626,"meta":757,"createdAt":774,"links":775},"cnH_T12_03","中药饮片 中成药 中药配方颗粒",[724,727,730,733,736,739,742,745,748,751,754],{"name":725,"note":726},"云南白药","000538，2025年营收411.87亿元",{"name":728,"note":729},"白云山","600332，2025年营收776.6亿元",{"name":731,"note":732},"华润三九","000999，2025年营收316亿元",{"name":734,"note":735},"片仔癀","600436",{"name":737,"note":738},"同仁堂","600085",{"name":740,"note":741},"康缘药业","600557，中药创新药",{"name":743,"note":744},"陕西步长制药有限公司","咸阳，脑心通胶囊等中成药生产",{"name":746,"note":747},"陕西盘龙药业集团股份有限公司","002864，商洛柞水，风湿骨伤类中成药",{"name":749,"note":750},"陕西汉王药业股份有限公司","汉中，中成药",{"name":752,"note":753},"陕西康惠制药股份有限公司","603139，咸阳，中成药",{"name":755,"note":756},"金花企业","集团",{"source":84,"experts":758,"policies":759,"chainCode":28,"aggregationZones":763},[],[760],{"raw":761,"date":544,"name":545,"doc_no":197,"issuer":546,"summary":762},"《医药工业数智化转型实施方案（2025—2030年）》（工业和信息化部等七部门，2025-04）：支持中药等细分行业开展数智化改造与智能工厂建设。","支持中药等细分行业开展数智化改造与智能工厂建设。",[764,766,768,770,772],{"city":172,"name":173,"note":765,"level":145},"汉江药业、汉王药业等医药企业集聚",{"city":175,"name":176,"note":767,"level":145},"现代中医与民族药特色产业集群",{"city":178,"name":179,"note":769,"level":155},"现代中药与中药材加工产业集聚",{"city":181,"name":182,"note":771,"level":145},"中药与天然药物产业化集聚",{"city":169,"name":170,"note":773,"level":145},"中药与创新药产业配套集聚","2026-10-12T14:28:54.487Z",[],{"id":777,"chainId":4,"layer":674,"segment":778,"name":778,"keyPoints":779,"companies":780,"sortOrder":497,"isKey":245,"checkState":626,"meta":796,"createdAt":816,"links":817},"cnH_T12_04","生物制品","疫苗 单抗 胰岛素 血液制品",[781,784,787,790,793],{"name":782,"note":783},"智飞生物","300122，疫苗与生物制品",{"name":785,"note":786},"万泰生物","603392，HPV疫苗等",{"name":788,"note":789},"沃森生物","300142，疫苗",{"name":791,"note":792},"长春高新","000661，金赛药业生长激素等生物药",{"name":794,"note":795},"天坛生物","600161，血液制品",{"source":84,"experts":797,"policies":801,"chainCode":28,"aggregationZones":805},[798],{"org":108,"raw":799,"name":110,"note":800,"title":91},"李校堃（温州医科大学），中国工程院院士，生长因子类生物药专家","生长因子类生物药专家",[802],{"raw":803,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":804},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：全链条支持创新生物药研发与临床应用。","全链条支持创新生物药研发与临床应用。",[806,808,810,812,814],{"city":184,"name":185,"note":807,"level":145},"疫苗与生长激素等生物制品产业集聚",{"city":166,"name":167,"note":809,"level":145},"疫苗与生物制品（中国生物）制造",{"city":143,"name":187,"note":811,"level":145},"疫苗与生物制品（中国医药城）",{"city":169,"name":170,"note":813,"level":145},"疫苗与血液制品等生物制品配套",{"city":160,"name":189,"note":815,"level":190},"生物药与细胞基因治疗产业化","2026-10-12T14:28:54.492Z",[],{"id":819,"chainId":4,"layer":674,"segment":820,"name":820,"keyPoints":821,"companies":822,"sortOrder":501,"isKey":245,"checkState":626,"meta":838,"createdAt":855,"links":856},"cnH_T12_05","医疗器械","高值耗材 影像设备 IVD",[823,826,828,830,832,835],{"name":824,"note":825},"迈瑞医疗","300760，生命信息与支持、IVD、影像",{"name":270,"note":827},"688271，高端医学影像",{"name":333,"note":829},"00853.HK",{"name":336,"note":831},"300003",{"name":833,"note":834},"鱼跃医疗","002223",{"name":836,"note":837},"威高股份","01066.HK",{"source":84,"experts":839,"policies":840,"chainCode":28,"aggregationZones":844},[],[841],{"raw":842,"date":256,"name":257,"doc_no":258,"issuer":259,"summary":843},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国办发〔2024〕53号）（国务院办公厅，2025-01）：深化医疗器械审评审批制度改革，支持高端医疗器械创新。","深化医疗器械审评审批制度改革，支持高端医疗器械创新。",[845,847,849,851,853],{"city":192,"name":193,"note":846,"level":145},"监护、影像与体外诊断器械制造集聚",{"city":163,"name":164,"note":848,"level":145},"高端医疗器械研发生产集聚",{"city":195,"name":196,"note":850,"level":197},"（上海市 · 市级）：高端医疗器械全链条产业集聚",{"city":199,"name":200,"note":852,"level":190},"医用耗材与敷料产业集聚",{"city":166,"name":202,"note":854,"level":145},"心血管介入器械等研制配套","2026-10-12T14:28:54.496Z",[],{"id":858,"chainId":4,"layer":859,"segment":860,"name":860,"keyPoints":861,"companies":862,"sortOrder":890,"isKey":652,"checkState":626,"meta":891,"createdAt":909,"links":910},"cnH_T12_06","下游","医药流通与医疗服务","医药商业 医院 连锁药房",[863,866,869,872,875,878,881,884,887],{"name":864,"note":865},"国药控股","01099.HK，2025年营收5752亿元，终端网络客户覆盖70余万家",{"name":867,"note":868},"上海医药","601607，2025年营收2835.8亿元",{"name":870,"note":871},"九州通","600998，2025年营收1613.9亿元",{"name":873,"note":874},"重药控股","000950",{"name":876,"note":877},"老百姓","603883",{"name":879,"note":880},"益丰药房","603939",{"name":882,"note":883},"陕西医药控股集团派昂医药有限责任公司","医药流通配送",{"name":885,"note":886},"西安怡康医药连锁有限责任公司","医药零售连锁",{"name":888,"note":889},"西安国际医学投资股份有限公司","000516，高新医院等医疗服务",5,{"source":84,"experts":892,"policies":893,"chainCode":28,"aggregationZones":900},[],[894,897],{"raw":895,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":896},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：要求提高创新药多元支付能力，推动创新药加速进入医疗机构。","要求提高创新药多元支付能力，推动创新药加速进入医疗机构。",{"raw":898,"date":298,"name":299,"doc_no":197,"issuer":300,"summary":899},"《商业健康保险创新药品目录（2025年）》（国家医保局、人力资源社会保障部，2025-12）：鼓励商业保险与基本医保错位发展，支持探索“一站式”结算。","鼓励商业保险与基本医保错位发展，支持探索“一站式”结算。",[901,903,905,907],{"city":204,"name":205,"note":902,"level":145},"医药流通与供应链（九州通）集聚",{"city":192,"name":207,"note":904,"level":145},"医药供应链与冷链物流配套",{"city":209,"name":210,"note":906,"level":145},"航空物流与医药物流配套",{"city":212,"name":213,"note":908,"level":197},"（上海市 · 国家级）：药品进出口与分销物流配套","2026-10-12T14:28:54.499Z",[],{"id":912,"chainId":4,"layer":632,"segment":913,"name":913,"keyPoints":914,"companies":915,"sortOrder":40,"isKey":652,"checkState":626,"meta":934,"createdAt":951,"links":952},"cnH_T12_07","医药研发外包与生产服务（CXO）","CRO\u002FCDMO服务连接化合物发现、临床研究与商业化生产，是医药创新体系的重要支撑环节",[916,919,922,925,928,931],{"name":917,"note":918},"药明康德","603259，2025年营收454.6亿元，持续经营业务在手订单580亿元",{"name":920,"note":921},"药明生物","02269.HK，2025年收益218亿元，未完成订单总额237亿美元",{"name":923,"note":924},"康龙化成","300759",{"name":926,"note":927},"泰格医药","300347",{"name":929,"note":930},"凯莱英","002821",{"name":932,"note":933},"昭衍新药","603127",{"source":84,"experts":935,"policies":936,"chainCode":28,"aggregationZones":940},[],[937],{"raw":938,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":939},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：支持研发外包服务与创新药研发链条协同发展。","支持研发外包服务与创新药研发链条协同发展。",[941,943,945,947,949],{"city":160,"name":161,"note":942,"level":145},"CRO\u002FCDMO企业高度集聚",{"city":143,"name":144,"note":944,"level":145},"CRDMO与CDMO产能集聚",{"city":163,"name":164,"note":946,"level":145},"生物药CDMO与研发外包配套",{"city":166,"name":167,"note":948,"level":145},"医药研发服务（CRO）企业集聚",{"city":215,"name":216,"note":950,"level":145},"小分子CDMO与连续反应技术配套","2026-10-12T14:28:54.503Z",[],{"id":954,"chainId":4,"layer":632,"segment":955,"name":955,"keyPoints":956,"companies":957,"sortOrder":969,"isKey":652,"checkState":626,"meta":970,"createdAt":987,"links":988},"cnH_T12_08","CXO研发生产服务","CRO(药物发现\u002F临床前\u002F临床)、CDMO(原料药\u002F制剂\u002F生物药生产外包)",[958,960,962,964,967],{"name":917,"note":959},"603259",{"name":920,"note":961},"02269.HK",{"name":929,"note":963},"002821，小分子CDMO",{"name":965,"note":966},"博腾股份","300363",{"name":643,"note":968},"603456",7,{"source":84,"experts":971,"policies":972,"chainCode":28,"aggregationZones":976},[],[973],{"raw":974,"date":292,"name":293,"doc_no":197,"issuer":294,"summary":975},"《支持创新药高质量发展的若干措施》（国家医保局、国家卫生健康委，2025-07）：鼓励创新药研发与产业化服务体系发展。","鼓励创新药研发与产业化服务体系发展。",[977,979,981,983,985],{"city":160,"name":161,"note":978,"level":145},"药明康德等CXO企业总部与研发集聚",{"city":218,"name":219,"note":980,"level":197},"国际生命科学园（无锡市 · 省级）：全流程CRDMO（药明康德）",{"city":221,"name":222,"note":982,"level":145},"生物药与ADC CDMO（药明生物）",{"city":224,"name":225,"note":984,"level":197},"（苏州市 · 国家级）：创新药与CXO企业高度集聚",{"city":215,"name":216,"note":986,"level":145},"小分子CDMO与连续反应技术平台","2026-10-12T14:28:54.506Z",[],{"id":990,"chainId":4,"layer":632,"segment":991,"name":991,"keyPoints":992,"companies":993,"sortOrder":1010,"isKey":652,"checkState":626,"meta":1011,"createdAt":1028,"links":1029},"cnH_T12_09","生物试剂\u002F培养基\u002F科研","重组蛋白\u002F抗体试剂、细胞培养基、原料药\u002F药用辅料、实验仪器",[994,997,1000,1002,1005,1008],{"name":995,"note":996},"诺唯赞","688105，分子类生物试剂与IVD原料",{"name":998,"note":999},"义翘神州","301047，重组蛋白与抗体原料",{"name":470,"note":1001},"688137，mRNA原料酶与诊断原料",{"name":1003,"note":1004},"百普赛斯","301080，重组蛋白",{"name":1006,"note":1007},"菲鹏生物","IVD核心原料",{"name":362,"note":1009},"688293，细胞培养基",8,{"source":84,"experts":1012,"policies":1016,"chainCode":28,"aggregationZones":1017},[1013],{"org":118,"raw":1014,"name":120,"note":1015,"title":122},"谭文松（华东理工大学），教授，动物细胞大规模培养与无血清培养基技术专家","动物细胞大规模培养与无血清培养基技术专家",[],[1018,1020,1022,1024,1026],{"city":227,"name":228,"note":1019,"level":145},"分子类生物试剂与IVD原料（诺唯赞）",{"city":166,"name":230,"note":1021,"level":145},"生命科学仪器与试剂研发集聚",{"city":232,"name":233,"note":1023,"level":145},"IVD核心原料与生物试剂研制配套",{"city":235,"name":236,"note":1025,"level":197},"（上海市 · 市级）：引物与基因合成、生物试剂",{"city":163,"name":238,"note":1027,"level":145},"生物试剂与科研上游配套集聚","2026-10-12T14:28:54.510Z",[],{"chainId":4,"chainName":5,"matchedTagNames":1031,"experts":1032,"achievements":1034,"topUniversities":1036,"note":1037},[],{"count":651,"items":1033},[],{"count":651,"items":1035},[],[],"无标签映射",{"hasMapping":652,"chainId":4,"segments":1039},[],[1041,1043,1045,1047,1049,1051,1053,1055,1057],{"name":89,"id":1042},"cmv7rhqtd01udhikyxoyqm8bn",{"name":95,"id":1044},"b3a3fb34-8269-103f-bb17-733af39bfb62",{"name":99,"id":1046},"cmv7rhowe0022hiky5r26cvh6",{"name":105,"id":1048},"d1013e_8386a64f8352cf12",{"name":110,"id":1050},"cmv7rhqti01uihikytwtk594t",{"name":115,"id":1052},"0e408e5a-e690-4d13-92fc-413df6566f3d",{"name":120,"id":1054},"cmv7rhqto01unhikybbzel32k",{"name":126,"id":1056},"b7340eff-7380-4453-87d0-355be107dd9d",{"name":132,"id":1058},"cmv7rhoxd002whikyb1h4oiek",{"list":1060,"total":1096,"page":490,"pageSize":1010,"totalPages":497},[1061,1066,1072,1078,1083,1090],{"id":1062,"name":1063,"category":6,"groupCategory":7,"intro":1064,"scale":197,"maturity":10,"checkState":626,"nodeCount":969,"companyCount":1065},"ch60_T08","传统汽车产业链","燃油车整车及零部件，向新能源汽车转型",119,{"id":1067,"name":1068,"category":6,"groupCategory":7,"intro":1069,"scale":197,"maturity":1070,"checkState":626,"nodeCount":40,"companyCount":1071},"ch60_T11","家电制造产业链","家用电器制造，向智能家电升级","成熟期",28,{"id":1073,"name":1074,"category":6,"groupCategory":7,"intro":1075,"scale":1076,"maturity":1070,"checkState":626,"nodeCount":969,"companyCount":1077},"9f188ad6-e927-4dda-afc4-dde4683089eb","工程机械产业链","工程机械、矿山机械、农业机械制造","2024年装备制造业增加值占规上工业34.6%；工业机器人产量55.6万套(+14.2%)、销量30.2万台占全球54%，机器人行业营收2378.9亿元(国家统计局\u002F工信部,2024)",57,{"id":1079,"name":1080,"category":6,"groupCategory":7,"intro":1081,"scale":197,"maturity":10,"checkState":626,"nodeCount":1010,"companyCount":1082},"ch60_T04","建材产业链","水泥、玻璃、陶瓷、新型建材",49,{"id":1084,"name":1085,"category":6,"groupCategory":7,"intro":1086,"scale":1087,"maturity":10,"checkState":626,"nodeCount":1088,"companyCount":1089},"52294d28-07dc-4f86-844f-6b5bea542726","建筑与房地产产业链","房屋建筑、土木工程建筑、建筑安装装饰","2024年全国建筑业总产值32.7万亿元、增加值约9万亿元，装配式建筑占新建建筑比例达30%以上(住建部,2024\u002F十四五)",10,72,{"id":1091,"name":1092,"category":6,"groupCategory":7,"intro":1093,"scale":1094,"maturity":1070,"checkState":626,"nodeCount":41,"companyCount":1095},"1e4e94ff-2688-4052-9a78-0fefebcd78cf","有色金属产业链","有色金属冶炼和压延加工，包含铜铝铅锌和稀有金属","2024年全国煤炭产量47.8亿吨、约占一次能源生产总量66.6%，煤矿智能化产能占比超50%(中国煤炭工业协会\u002F国家能源局,2024)",138,19]